IP Library Granted Patent US 11,753,465
Granted Patent B2
US 11,753,465 · App. 17/188,158 · Granted Sep 12, 2023

Nucleic acids encoding polypeptides against IL-23

Inventor: Marie-Ange Buyse (Merelbeke, BE)
Assignees: Ablynx N.V.; Sanofi
C07K16/244A61P35/00A61P31/00C07K16/4208C07K2317/22C07K2317/34C07K2317/56C07K2317/569
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,753,465
App. No.
17/188,158
Granted
Sep 12, 2023
Kind
B2
Abstract

The present invention relates to amino acid sequences that are directed against interleukin 23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODY® molecules against IL-23 and one NANOBODY® molecule against serum albumin, linked by two linkers. In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1 ) (also referred to herein as “anti-IL 23 polypeptides of the invention”).

Claims (14)

1. A nucleic acid that encodes an anti-interleukin 23 (IL-23) polypeptide comprising an amino acid sequence that is chosen from the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3.

2. A nucleic acid that encodes an anti-interleukin 23 (IL-23) polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

3. A nucleic acid that encodes an anti-interleukin 23 (IL-23) polypeptide comprising the amino acid sequence of SEQ ID NO: 3.

4. A non-human host or an isolated host cell that comprises the nucleic acid of claim 1 .

5. A non-human host or an isolated host cell that comprises the nucleic acid of claim 2 .

6. A non-human host or an isolated host cell that comprises the nucleic acid of claim 3 .

7. A method for producing an anti-IL-23 polypeptide, wherein said method comprises

expressing the anti-IL-23 polypeptide encoded by the nucleic acid of claim 1 in a non-human host or an isolated host cell.

8. The method of claim 7 , further comprising isolating and/or purifying the anti-IL-23 polypeptide.

9. A method for producing an anti-IL-23 polypeptide, wherein said method comprises cultivating the

non-human host or isolated host cell of claim 4 under conditions that are such that said non-human host or isolated host cell expresses the anti-IL-23 polypeptide encoded by the nucleic acid.

10. The method of claim 9 , further comprising isolating and/or purifying the anti-IL-23 polypeptide.

11. A method for producing an anti-IL-23 polypeptide, wherein said method comprises maintaining the non-human host or isolated host cell of claim 4 under conditions that are such that said non-human host or isolated host cell expresses the anti-IL-23 polypeptide encoded by the nucleic acid.

12. The method of claim 11 , further comprising isolating and/or purifying the anti-IL-23 polypeptide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: ABLYNX N.V.
To: SANOFI
Reel/Frame 059883/0339 →
CONFIRMATORY ASSIGNMENT Recorded May 13, 2021
From: BUYSE, MARIE-ANGE
To: ABLYNX N.V.
Reel/Frame 056229/0660 →
Continuity (3)
Continuation 15769864
Provisional Application 62248468 · Oct 30, 2015
Related Publication 20210188967A1 · Jun 24, 2021
Cited By (1)
US 50,682